Cost-effectiveness of edoxaban versus rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) in the US

Cost-effectiveness of edoxaban versus rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) in the US

Jeffrey D Miller,1 Xin Ye,2 Gregory M Lenhart,1 Amanda M Farr,1 Oth V Tran,1 W Jackie Kwong,2 Elizabeth A Magnuson,3 William S Weintraub41Truven Health Analytics Inc, Cambridge, MA, 2Daiichi Sankyo Inc, Parsippany, NJ, 3St Luke Mid-America Heart Institute, Kansas City, MO, 4Center for Heart and Vasc...

Full description

Bibliographic Details
Main Authors:	Miller JD, Ye X, Lenhart GM, Farr AM, Tran OV, Kwong WJ, Magnuson EA, Weintraub WS
Format:	Article
Language:	English
Published:	Dove Medical Press 2016-05-01
Series:	ClinicoEconomics and Outcomes Research
Subjects:	edoxaban rivaroxaban cost-effectiveness non-valvular atrial fibrillation oral anticoagulation stroke
Online Access:	https://www.dovepress.com/cost-effectiveness-of-edoxaban-versus-rivaroxaban-for-stroke-preventio-peer-reviewed-article-CEOR

Similar Items

Postmarketing surveillance on the clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA‐AF‐Japan): One‐year safety and effectiveness analyses
by: Takeshi Yamashita, et al.
Published: (2020-06-01)

Are outpatient anticoagulation management services the wave of the future (again)?
by: Bethany Samuelson Bannow
Published: (2022-05-01)

Postmarketing surveillance on clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA‐AF‐Japan): Three‐month interim analysis results
by: Takeshi Yamashita, et al.
Published: (2019-02-01)

Safety and effectiveness of edoxaban in Japanese patients with nonvalvular atrial fibrillation: Final report of a two‐year postmarketing surveillance study (ETNA‐AF‐Japan)
by: Takeshi Yamashita, et al.
Published: (2021-04-01)

Beneficial Effect of Edoxaban on Preventing Atrial Fibrillation and Coagulation by Reducing Inflammation via HBG1/HBD Biomarkers
by: Chenguang Yang, et al.
Published: (2022-06-01)

Non-Vitamin K Antagonist Oral Anticoagulants in Patients with β-Thalassemia
by: Michele Malagù, et al.
Published: (2023-03-01)

Risk management in patients with atrial fibrillation and comorbid conditions: potentialities of edoxaban
by: O. L. Barbarash, et al.
Published: (2020-11-01)

Anticoagulation in the early phase of non-valvular atrial fibrillation-related acute ischemic stroke: where do we stand?
by: Luca Masotti, et al.
Published: (2019-01-01)

Study design of GENERAL (general practitioners and embolism prevention in NVAF patients treated with rivaroxaban: Real-life evidence): A multicenter prospective cohort study in primary care physicians to investigate the effectiveness and safety of rivaroxaban in Japanese patients with NVAF
by: Kengo Kusano, MD, PhD, et al.
Published: (2017-08-01)

Direct oral anticoagulants; a review for the non-specialist
by: Thilina Gunawardena
Published: (2021-11-01)

Gastrointestinal Bleeding and Direct Oral Anticoagulants among Patients with Atrial Fibrillation: Risk, Prevention, Management, and Quality of Life
by: Paolo Zappulla, et al.
Published: (2021-04-01)

Renal outcomes of rivaroxaban compared with warfarin in Asian patients with nonvalvular atrial fibrillation: A nationwide population-based cohort study
by: So-Ryoung Lee, et al.
Published: (2023-02-01)

Efficacy and Safety of Edoxaban in Patients With Active Malignancy and Atrial Fibrillation: Analysis of the ENGAGE AF‐TIMI 48 Trial
by: Christina L. Fanola, et al.
Published: (2018-08-01)

Edoxaban in venous thromboembolism and stroke prevention: an appraisal
by: Proietti M, et al.
Published: (2016-02-01)

Prediction and Implications of Edoxaban-Associated Bleeding in Patients after Critical Illness
by: Ryusei Mikami, et al.
Published: (2023-01-01)

Effect of Rivaroxaban in Stroke Prevention in Patient with Atrial Fibrillation due to Valvular Heart Disease
by: Waqar shamim, et al.
Published: (2022-02-01)

Cost effectiveness of rivaroxaban versus warfarin among nonvalvular atrial fibrillation patients in Saudi Arabia: A Single–Center retrospective cohort study
by: Yazed AlRuthia, et al.
Published: (2023-01-01)

Periinterventional Management of Edoxaban in Major Procedures: Results from the DRESDEN NOAC REGISTRY
by: Christina Köhler, et al.
Published: (2023-07-01)

The edoxaban‐M4 metabolite and measurement of edoxaban by chromogenic assays in human plasma
by: Romain Siriez, et al.
Published: (2022-03-01)

Effect of edoxaban compared with other oral anticoagulants for stroke prevention in patients with atrial fibrillation: A meta-analysis
by: Bailin Zhang, et al.
Published: (2023-11-01)

Safety and efficacy of uninterrupted treatment with edoxaban or warfarin during the peri‐procedural period of catheter ablation for atrial fibrillation
by: Kazuya Naito, et al.
Published: (2020-08-01)

Safety and Effectiveness of Edoxaban in Atrial Fibrillation Patients in Routine Clinical Practice: One-Year Follow-Up from the Global Noninterventional ETNA-AF Program
by: Raffaele De Caterina, et al.
Published: (2021-02-01)

PHARMACOGENETIC ASPECTS OF NEW ORAL ANTICOAGULANTS APPLICATION
by: A. V. Kryukov, et al.
Published: (2017-07-01)

Direct oral anticoagulants: a guide for daily practice
by: Pierre Fontana, et al.
Published: (2016-02-01)

Effectiveness and safety of edoxaban versus warfarin in patients with nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies
by: Mohammed M. Alsultan, et al.
Published: (2023-11-01)

Comparative Effectiveness and Safety of Dabigatran and Rivaroxaban in Atrial Fibrillation Patients
by: Chao‐Lun Lai, et al.
Published: (2017-04-01)

Determination of Anti-Xa Inhibitor Plasma Concentrations Using a Universal Edoxaban Calibrator
by: Annika Burger, et al.
Published: (2023-06-01)

A retrospective study of real-world effectiveness and safety of rivaroxaban in patients with non-valvular atrial fibrillation and venous thromboembolism in Saudi Arabia
by: Hind M. Alosaimi, et al.
Published: (2022-09-01)

Rivaroxaban in non valvular atrial fibrillation: subgroups analysis
by: Cesare Greco
Published: (2015-08-01)

NOVEL ANTICOAGULANTS FOR THROMBOEMBOLIC COMPLICATIONS PREVENTION IN NONVALVULAR ATRIAL FIBRILLATION
by: D. A. Itkin, et al.
Published: (2015-02-01)

Application of plasma metabolome for monitoring the effect of rivaroxaban in patients with nonvalvular atrial fibrillation
by: Mindi Zhao, et al.
Published: (2022-08-01)

A study on the role of rivaroxaban in management of venous thromboembolism
by: Mohmed Abdalwahab, et al.
Published: (2015-10-01)

Gastrointestinal Bleeding Due to NOACs Use: Exploring the Molecular Mechanisms
by: Angela Saviano, et al.
Published: (2022-11-01)

Use of direct oral anticoagulants for the prevention and treatment of thromboembolic disease in patients with reduced renal function: a short review of the clinical evidence
by: Willett KC, et al.
Published: (2017-04-01)

The impact of prothrombin complex concentrates when treating DOAC-associated bleeding: a review
by: Maureane Hoffman, et al.
Published: (2018-12-01)

Rivaroxaban in atrial fibrillation cardioversion: an update
by: Lavalle C, et al.
Published: (2019-05-01)

Stroke prevention in the elderly atrial fibrillation patient with comorbid conditions: focus on non-vitamin K antagonist oral anticoagulants
by: Turagam MK, et al.
Published: (2015-09-01)

Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation
by: Faye L. Norby, et al.
Published: (2017-09-01)

International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER)
by: Jan Beyer-Westendorf, et al.
Published: (2019-04-01)

Successful Cerebral Hemorrhage Control with Prothrombin Complex Concentrate in a Patient on Edoxaban Therapy: A Case Report
by: Galbiati G
Published: (2020-01-01)